Drugs / FPT155
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04074759 | Oct 2018 → Aug 2021 | cancer | Five Prime Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPT155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04074759 ↗ |
| Known as | Cd80-fc fusion protein fpt155 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594364 ↗ |
| Modality | Protein / enzyme biologic | “A soluble CD80 fusion protein” NCT04074759 ↗ |